The GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTUse code WELCOME10 for 10% off your orderFREE FEDEX 2-DAY shipping on orders over $250!Military · Veterans · First Responders: Verify & Save →Free gift on orders $300+ · choose GLP-3 RT 5MG, GHK-Cu 100MG, NAD+ 500MG or MOTs-C 10MGUse code WELCOME10 for 10% off your orderFREE FEDEX 2-DAY shipping on orders over $250!Military · Veterans · First Responders: Verify & Save →
Research Guide

Piracetam
Research Guide

A Research Use Only reference to Piracetam: identity data, what published studies examined, handling and storage for laboratories.

Research reference · Updated October 9, 2026 · How we check our guides

What is piracetam?

Piracetam (2-oxo-1-pyrrolidineacetamide, research code UCB 6215, trade name Nootropil) is a synthetic compound, a 2-pyrrolidinone ring with an acetamide group on its nitrogen, and the first racetam. A 2001 Lancet review traces it to Corneliu Giurgea's research in the late 1960s and credits him with coining the word "nootropic" (Shorvon, 2001). Most of the world's piracetam has been marketed by the Belgian company UCB (Flicker and Grimley Evans, 2001).

It is a prescription medicine in many European countries (Cohen et al., 2020), but the US Food and Drug Administration (FDA) has not approved it. Disguised Alpha supplies piracetam in 600MG capsules, as listed on the product page, for laboratory research use only. Nothing on this page is guidance for use in people.

Piracetam reference data

PropertyValue
NamePiracetam
Also calledUCB 6215, Nootropil (UCB trade name), 2-oxo-1-pyrrolidineacetamide, 2-(2-oxopyrrolidin-1-yl)acetamide (PubChem CID 4843)
StructureA 2-pyrrolidinone ring (a five-membered lactam) with an acetamide group on the ring nitrogen; no stereocenters
Compound classRacetam (2-oxopyrrolidine acetamide), the parent compound of the racetam family
Molecular formulaC₆H₁₀N₂O₂
Molecular weight142.16 g/mol
PubChem CID4843
FormCapsules, 600MG per capsule, as listed on the product page
TestingThird-party tested, with the certificate for each lot published on the product page and in the COA portal

Capsule format, strength and storage are from the product page; the formula, molecular weight, synonyms and structure are from PubChem CID 4843. The two sources do not conflict.

See it beside the other compounds on this site in the peptide molecular weight reference table.

What the research covers

Published piracetam research falls into six areas, each with its model stated below. Mechanism data come from cells, membranes and animals; the human trials are mostly older and small, with mixed findings.

Proposed mechanisms: membranes and AMPA receptors

The piracetam mechanism is not settled (Shorvon, 2001). In vitro, 0.1 to 1.0 mM piracetam raised the fluidity of brain membranes from aged mice, rats and humans but not from young mice; in rats given 300 mg/kg once daily, regional membrane fluidity and active avoidance learning rose in aged animals only (Müller et al., 1997).

In cultured cerebellar granule cells, micromolar piracetam raised AMPA-stimulated calcium influx, increasing efficacy rather than potency, and it raised AMPA binding site density in rat cortical membranes (Copani et al., 1992). In GluA2 and GluA3 crystal structures, piracetam sits at several low-occupancy sites along the interface between two subunits, while aniracetam binds one central site (Ahmed and Oswald, 2010). Models: brain membranes, neuron cultures, rats and receptor crystals.

Red cell deformability

Filtering oxygenated sickle cell (HbSS) red cells through polycarbonate microsieves showed that piracetam raised their deformability in vitro, and the authors reported a similar change in vivo after oral intake (Gini and Sonnet, 1987). A Cochrane review of three trials with 169 participants found insufficient reliable evidence to support routine use of piracetam for preventing painful sickle cell crises (Al Hajeri and Fedorowicz, 2016). Models: sickle red cells and human trials.

Rodent memory models

Rodent findings depend on age, genotype and task. Young male rats given 250 mg/kg chronically learned a spatial three-choice task faster, but they extinguished it more slowly and were impeded in reversal learning (Christoffersen et al., 1998). Male Ts65Dn mice, a Down syndrome model, and euploid mice received 0, 75, 150 or 300 mg/kg intraperitoneally each day, starting 4 weeks before Morris water maze testing.

Euploid mice at 75 and 150 mg/kg performed better on the visible and hidden platform tasks, but in Ts65Dn mice every amount prevented the usual gains across trials, and the authors wrote that the data do not support its use in Down syndrome (Moran et al., 2002). These are animal data only. Models: rats and mice.

Cortical myoclonus

The Lancet review notes piracetam's licensing for its antimyoclonic action and for effects after stroke and in mild cognitive impairment (Shorvon, 2001). In a double-blind, placebo-controlled crossover trial, 21 people with disabling myoclonus, all but one with electrophysiological signs of cortical origin and all chosen after apparent responses to piracetam, received 14 days of each, mostly alongside other antimyoclonic drugs.

Ten needed rescue from the placebo phase because their myoclonus worsened severely, none from the piracetam phase, and total rating scores differed significantly in favor of piracetam, by a median of 22 percent (Brown et al., 1993). In 20 people aged 17 to 43 with Unverricht-Lundborg disease, a progressive myoclonus epilepsy, a multicenter, randomized, double-blind crossover trial of placebo and two of three daily amounts found significant changes in the primary rating score at the highest amount (Koskiniemi et al., 1998). Model: human crossover trials.

Dementia and cognitive impairment reviews

A 2001 Cochrane review found that many trials were crossovers without usable first-phase data. Only global impression of change had enough pooled data; it favored piracetam (fixed-effects odds ratio 3.55, 95% CI 2.45 to 5.16, with heterogeneity), while effects on cognition and other measures were inconclusive, and the reviewers concluded that the published evidence does not support piracetam for dementia or cognitive impairment (Flicker and Grimley Evans, 2001).

A 2002 meta-analysis led by a UCB researcher pooled 19 double-blind, placebo-controlled studies in older adults with dementia or cognitive impairment and reported a significant odds ratio favoring piracetam on clinical global impression of change (Waegemans et al., 2002). A 2024 meta-analysis of 18 studies in 886 adults with memory impairment found no clear memory difference (standardized mean difference 0.75, 95% CI -0.19 to 1.69, I² 96%) (Gouhie et al., 2024). Model: meta-analyses of human trials.

Post-stroke aphasia and cerebral blood flow

In a double-blind trial in 24 people with aphasia after stroke, all given speech therapy, PET showed significant rises in task-related blood flow activation in three left-hemisphere language regions after 6 weeks with piracetam, against only the left vocalization area with placebo, and the piracetam group gained on 6 language functions against 3 subtests for placebo (Kessler et al., 2000).

A 2016 meta-analysis of 7 randomized trials with 261 people found no significant difference in overall aphasia severity (standardized mean difference 0.23, 95% CI -0.03 to 0.49) but one in written language (0.35, 95% CI 0.04 to 0.66). The effect appeared early and declined, and the authors described a limited role (Zhang et al., 2016). Models: human randomized trials, PET imaging and a meta-analysis.

Key studies

  1. Brown P, et al. "Effectiveness of piracetam in cortical myoclonus." Mov Disord. 1993. PMID 8419809. DOI 10.1002/mds.870080112. Double-blind crossover in 21 people with myoclonus.
  2. Müller WE, et al. "Effects of piracetam on membrane fluidity in the aged mouse, rat, and human brain." Biochem Pharmacol. 1997. PMID 9037245. DOI 10.1016/s0006-2952(96)00463-7. Brain membranes and aged rats.
  3. Flicker L, Grimley Evans G. "Piracetam for dementia or cognitive impairment." Cochrane Database Syst Rev. 2001. PMID 11405971. DOI 10.1002/14651858.CD001011. Cochrane review: evidence did not support it.
  4. Moran TH, et al. "The effects of piracetam on cognitive performance in a mouse model of Down's syndrome." Physiol Behav. 2002. PMID 12419416. DOI 10.1016/s0031-9384(02)00873-9. Ts65Dn mice: water maze gains blocked.
  5. Zhang J, et al. "Piracetam for Aphasia in Post-stroke Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials." CNS Drugs. 2016. PMID 27236454. DOI 10.1007/s40263-016-0348-1. 7 trials, 261 people.

Handling and storage of piracetam capsules

General laboratory practice for this material:

  • Store the sealed capsules at 15 to 25°C in the original container (a sealed bottle or resealable pouch, depending on the batch), away from moisture and direct light, as the product page lists. Close it fully after each opening.
  • Record the lot number and keep its certificate. Each lot's certificate reports its HPLC purity and the measured content per capsule; use the measured value for quantitative work.
  • For identity checks, compare data with C₆H₁₀N₂O₂, 142.16 g/mol and a monoisotopic mass of 142.07 (PubChem CID 4843). With no stereocenters, no chiral method is needed.

Frequently asked questions

What is piracetam?

Piracetam is 2-oxo-1-pyrrolidineacetamide (PubChem CID 4843), the first racetam, which traces to Corneliu Giurgea's research in the late 1960s (Shorvon, 2001).

Is piracetam a racetam?

Yes. It is the first racetam (Shorvon, 2001) and the parent compound the family is named after. Oxiracetam, aniracetam and phenylpiracetam keep its 2-oxopyrrolidine ring with different groups attached, as our racetams explainer shows.

What is piracetam's mechanism of action?

No single target is established (Shorvon, 2001). Proposed mechanisms include higher fluidity in aged brain membranes (Müller et al., 1997), AMPA receptor modulation in neuron cultures (Copani et al., 1992) and greater red cell deformability (Gini and Sonnet, 1987), mainly from cell, tissue and animal data.

Piracetam vs Noopept: how do they differ?

Noopept (omberacetam, GVS-111) is N-phenylacetyl-L-prolylglycine ethyl ester (PubChem CID 180496, 318.4 g/mol), a dipeptide derivative without piracetam's 2-oxopyrrolidine ring, so by structure it is not a racetam. Piracetam has been tested in randomized, placebo-controlled trials; PubMed indexes no randomized controlled trial of Noopept (searched October 2026). See our Noopept research guide.

Is piracetam FDA approved?

No. Drugs@FDA lists no product containing piracetam (openFDA search, October 2026). A 2019 FDA warning letter called one seller's piracetam, sold with memory and disease claims, an unapproved new drug, noting that the letter did not address whether piracetam can be lawfully marketed as a dietary supplement. Testing found piracetam in 4 of 5 supplement brands bought online (Cohen et al., 2020). In Europe, a European Medicines Agency list dated January 2023 shows piracetam medicines nationally authorized in 23 EU countries plus Norway and Northern Ireland, nearly all held by UCB companies.

Where can researchers buy piracetam?

Disguised Alpha sells piracetam for laboratory research as 600MG capsules, as listed on the product page, which also shows stock status and each lot's third-party certificate: Piracetam.

Related compounds and guides

This product is for research use only. It has not been evaluated for safety or effectiveness in humans. Not for human consumption. All products are intended for laboratory research purposes only.

Certificates of analysis

Each tested batch of Piracetam has its own certificate page with the full lab results.

25% offGLPs15% off automaticallyUse code GLP or any code for 25% off0days00hrs00min00secShop the sale  →Shop